The report will be distributed in July 2014 and will analyze current and future trends across the U.S. pharma landscape. It will feature expert opinions from European companies, contrasted with U.S. internal perceptions to provide an overview of business practices the region. It will also examine the areas in which European companies are looking to work with U.S. companies, as well as import into the U.S. and domestic and export manufacturing across the fine, specialty and custom chemicals market.
Chris Kilbee, group director, CPhI said, “USA, as the largest pharma market, is a key driver of leading innovations across the global industry. CPhI is committed to analyzing the prominent pharma economies to help suppliers identify growth opportunities and encourage partnerships. European perspectives on the U.S. market will generate insights that will be valuable, not only in Europe and the U.S., but also for any other regions looking to invest in, or work with, the World’s premier pharma economy.”